GlaxoSmithKline (GSK) Consumer Healthcare announced March 27 that the company is voluntarily recalling all alli® weight loss products from U.S. and Puerto Rico retailers as the company believes that some packages of the product were tampered with and may contain product that is not authentic alli. GSK is conducting an investigation and is working with the knowledge of the U.S. Food and Drug Administration (FDA) on this retailer level recall.
During the time of GSK’s press release announcement, Healthcare Packaging (HCP) was visiting different organizations in Washington, DC, where the topic of recalls in general was a key concern. HCP was told that FDA is reaching out to industry and other stakeholders to address the issue, looking at quality aspects involving production, manufacturing, materials, packaging, and distribution, among other issues.
